Life Sciences

Scientists at University of Munich discuss research in life sciences

Published in Hepatitis Weekly, December 28th, 2009

According to a study from Munich, Germany, "The transcription factor nuclear factor kappa B (NF-kappa B) has risen as a promising target for anti-inflammatory therapeutics. In the liver, however, NF-kappa B inhibition mediates both damaging and protective effects."

"The outcome is deemed to depend on the liver cell type addressed. Recent gene knock-out studies focused on the role of NF-kappa B in hepatocytes, whereas the role of NF-kappa B in Kupffer cells has not yet been investigated in vivo. Here we present a novel approach, which may be suitable for clinical application, to selectively target NF-kappa B in Kupffer cells and analyse the effects in experimental models...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Hepatitis Weekly

Source: Hepatitis Weekly (2009-12-28)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry